Literature DB >> 2841411

Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice.

C M Lawson1, J E Grundy, G R Shellam.   

Abstract

The role of antibodies as mediators of genetically determined resistance to murine cytomegalovirus (MCMV) in mice has not been elucidated. The ability of mice with different MCMV resistance phenotypes to produce an antibody response to MCMV was investigated in order to assess whether the host genotypes that control resistance also influence antibody production. Antibodies to MCMV in the sera of resistant (BALB.K, CBA/CaH, B10.BR) and susceptible [BALB/c, BALB.B, C57BL/10ScSn (B10), B10.D2, B10.A, A/J] mice were determined by ELISA and/or a complement-requiring neutralization assay. IgM antibodies were produced by all strains of mice as early as 3 to 5 days post-infection (p.i.) with maximum titres observed after 10 days p.i. for some strains, whilst IgG antibodies were produced by 5 to 7 days p.i. with maximum titres at 20 days p.i. IgA antibodies were not detected in the sera of MCMV-infected mice. Virulent MCMV induced higher antibody titres than either attenuated or u.v.-inactivated forms of the virus. Although high doses of virulent virus delayed the early production of IgM antibody they did not adversely affect the kinetics of IgG antibody production. High titres of neutralizing antibodies were detected as early as day 3 post-inoculation of virulent virus; when attenuated virus was used in the neutralization assay, this was found to be more easily neutralized than salivary gland-derived virus. Interestingly, although guinea-pig complement greatly enhanced antibody-mediated neutralization of MCMV, mouse complement was also effective at enhancing neutralization. Although genetically determined resistance to MCMV is an early event with the resistant phenotype being demonstrable during the first few days of the infection, there was no evidence that antibodies were responsible for this resistance since neither antibody titres nor the time of first appearance of antibody correlated with resistance status. However, these results do not exclude a more general role for antibody in limiting MCMV infection, especially in immunity to re-infection since passively transferred antibodies from resistant or susceptible mouse strains lowered virus titres in MCMV-infected animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841411     DOI: 10.1099/0022-1317-69-8-1987

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?

Authors:  Fathiah S Amran; Kyungchul Kim; Andrew Lim; Rachel Thomson; Silvia Lee; Grant Waterer; Patricia Price
Journal:  J Clin Immunol       Date:  2016-01-13       Impact factor: 8.317

2.  Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.

Authors:  Suzanne P M Welten; Anke Redeker; René E M Toes; Ramon Arens
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  The effects of protein malnutrition on the pathogenesis of murine cytomegalovirus disease.

Authors:  H K Teo; P Price; J M Papadimitriou
Journal:  Int J Exp Pathol       Date:  1991-02       Impact factor: 1.925

4.  Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice.

Authors:  J C Lenzo; G R Shellam; C M Lawson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis.

Authors:  H L O'Donoghue; C M Lawson; W D Reed
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

6.  Molecular and biological characterization of new strains of murine cytomegalovirus isolated from wild mice.

Authors:  T W Booth; A A Scalzo; C Carrello; P A Lyons; H E Farrell; G R Singleton; G R Shellam
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

Authors:  Steven R Wilson; Jean H Wilson; Linda Buonocore; Amy Palin; John K Rose; Jon D Reuter
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 8.  MHC class I immune evasion in MCMV infection.

Authors:  Carmen M Doom; Ann B Hill
Journal:  Med Microbiol Immunol       Date:  2008-03-11       Impact factor: 3.402

9.  Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity.

Authors:  C M Lawson; H L O'Donoghue; H E Farrell; G R Shellam; W D Reed
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

10.  CD28/B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection.

Authors:  Charles H Cook; Li Chen; Jin Wen; Peter Zimmerman; Yingxue Zhang; Joanne Trgovcich; Yang Liu; Jian-Xin Gao
Journal:  Viral Immunol       Date:  2009-04       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.